Reuters logo
BRIEF-Cellectar Biosciences says cohort 1, cohort 2 patients demonstrated post treatment median survival of 11.9 months, 4.9 months, respectively
December 1, 2016 / 1:20 PM / 10 months ago

BRIEF-Cellectar Biosciences says cohort 1, cohort 2 patients demonstrated post treatment median survival of 11.9 months, 4.9 months, respectively

Dec 1 (Reuters) - Cellectar Biosciences Inc :

* Cellectar Biosciences announces results from the first two cohorts of its CLR 131 phase 1 trial: demonstrates excellent efficacy, overall survival benefit, and progression free survival similar to or better than recently approved therapies

* Cellectar Biosciences Inc - cohort 1 and cohort 2 patients have demonstrated post treatment median survival of 11.9 months and 4.9 months, respectively

* Cellectar Biosciences - median survival for all evaluable patients in both cohorts continues to increase, to be followed to determine overall survival benefit

* Cellectar Biosciences Inc - currently, median overall survival (mos) for each cohort is not yet evaluable

* Cellectar Biosciences Inc - company is currently enrolling patients into study’s third cohort at a single 25 mci/m(2) dose

* Cellectar Biosciences Inc - plans to provide additional data update from study’s third cohort at a single 25 mci/m(2) dose, in first half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below